Medication Adjustments for Uncontrolled Hypertension in ESRD Patients
Introduction to Guideline-Directed Therapy
- The American Heart Association recommends that hydralazine without a nitrate is explicitly contraindicated in patients with hypertension and should be avoided (Class III Harm) 1, 2, 3
- The American College of Cardiology suggests that the combination of hydralazine plus isosorbide dinitrate has demonstrated a 43% mortality reduction and improved outcomes in patients with heart failure, particularly in Black patients (Class I, Level of Evidence A) 4
Blood Pressure Management Strategy
- The American Heart Association recommends starting an ACE inhibitor or ARB as first-line therapy, though note these are less effective for BP control in Black patients compared to other racial groups 4
- The American College of Cardiology suggests optimizing loop diuretic dosing, as the current furosemide dosing is inadequate, and loop diuretics should be used for volume control in patients with severe renal impairment (eGFR <30 mL/min) 1, 2, 3
- The American Heart Association recommends adding a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) which improves outcomes and lowers BP (Class I, Level of Evidence A) 1, 2, 3
Target Blood Pressure
- The American College of Cardiology suggests aiming for BP <130/80 mmHg, with consideration for lowering to <120/80 mmHg 6, 2, 3
Critical Medication Interactions and Monitoring
- The American Heart Association recommends avoiding non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they can depress myocardial function (Class III) 1, 2, 3
- The American College of Cardiology suggests avoiding clonidine and moxonidine as they are associated with increased mortality in heart failure (Class III) 1, 2, 3
- The American Heart Association recommends avoiding alpha-blockers (doxazosin) and using them only if all other options fail at maximum doses 1, 2, 3